Evaxion Receives Nasdaq Notification

May 10, 2024

Press releases

Evaxion Receives Nasdaq Notification

Evaxion announces that on May 7, 2024, it received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders’ equity requirement.

Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens

Apr 24, 2024

Publications

Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens

Publication: Frontiers in Immunology
Authors: Michail Angelos Pavlidis, Nadia Viborg, Mads Lausen, Birgitte Rønø and Daniela Kleine-Kohlbrecher

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Apr 17, 2024

Press releases

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Evaxion announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).

Startups probe hidden viruses in the ‘dark genome’ to treat disease

Apr 17, 2024

Publications

Startups probe hidden viruses in the ‘dark genome’ to treat disease

Publication: Nature Biotechnology
Author: Michael Eisenstein

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Apr 2, 2024

Press releases

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus).

Evaxion Announces Business Update and Full Year 2023 Financial Results

Mar 27, 2024

Press releases

Evaxion Announces Business Update and Full Year 2023 Financial Results

Evaxion today provides a business update and announces full year 2023 financial results.

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Mar 19, 2024

Press releases

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Evaxion hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform.

R&D Day on AI-Immunology™ March 19, 2024

Mar 19, 2024

Presentations

R&D Day on AI-Immunology™ March 19, 2024

Take a look at the presentations from our Research & Development (R&D) Day on AI-Immunology™ captured in a series of videos. 

Personalized Neoantigen DNA Cancer Vaccines: Current Status and Future Perspectives

Mar 14, 2024

Publications

Personalized Neoantigen DNA Cancer Vaccines: Current Status and Future Perspectives

Publication: Journal of Cellular Immunology
Author: Nadia Viborg, Daniela Kleine-Kohlbrecher and Birgitte Rønø

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Feb 29, 2024

Press releases

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Evaxion announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST.

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Feb 20, 2024

Press releases

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Evaxion announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique capabilities and know-how.

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 7, 2024

Press releases

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Evaxion announces that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).

Evaxion Media kit

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.